Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

Articolo

Data di Pubblicazione:

2023

Citazione:

Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) / F. Salton, P. Confalonieri, S. Centanni, M. Mondoni, N. Petrosillo, P. Bonfanti, G. Lapadula, D. Lacedonia, A. Voza, N. Carpenè, M. Montico, N. Reccardini, G.U. Meduri, B. Ruaro, M. Confalonieri. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 1399-3003. - 61:4(2023 Apr), pp. 2201514.1-2201514.10. [10.1183/13993003.01514-2022]

Abstract:

Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.

Tipologia IRIS:

01 - Articolo su periodico

Elenco autori: